For clear cell renal cell carcinoma, head and neck cancer, hepatocellular carcinoma, and pancreatic ductal adenocarcinoma, patients with high HMGA2 expression have shorter overall survivals. This evidence concerns the gene HMGA2 and hepatocellular carcinoma.